KR101548340B1 - Hangover recovery drink using bean sprouts and manufacturing method thereof - Google Patents
Hangover recovery drink using bean sprouts and manufacturing method thereof Download PDFInfo
- Publication number
- KR101548340B1 KR101548340B1 KR1020140009227A KR20140009227A KR101548340B1 KR 101548340 B1 KR101548340 B1 KR 101548340B1 KR 1020140009227 A KR1020140009227 A KR 1020140009227A KR 20140009227 A KR20140009227 A KR 20140009227A KR 101548340 B1 KR101548340 B1 KR 101548340B1
- Authority
- KR
- South Korea
- Prior art keywords
- bean sprouts
- water
- extract
- cultivation
- weight
- Prior art date
Links
- 244000046052 Phaseolus vulgaris Species 0.000 title claims abstract description 89
- 235000010627 Phaseolus vulgaris Nutrition 0.000 title claims abstract description 89
- 206010019133 Hangover Diseases 0.000 title claims abstract description 47
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 238000011084 recovery Methods 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 86
- 239000000284 extract Substances 0.000 claims abstract description 78
- 235000013361 beverage Nutrition 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 16
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 11
- 241000018646 Pinus brutia Species 0.000 claims abstract description 11
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 244000068988 Glycine max Species 0.000 claims description 34
- 235000010469 Glycine max Nutrition 0.000 claims description 34
- 238000000605 extraction Methods 0.000 claims description 27
- 229920001542 oligosaccharide Polymers 0.000 claims description 14
- 150000002482 oligosaccharides Chemical class 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 34
- 239000001301 oxygen Substances 0.000 abstract description 34
- 229910052760 oxygen Inorganic materials 0.000 abstract description 34
- 244000010000 Hovenia dulcis Species 0.000 abstract description 6
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 105
- 238000012360 testing method Methods 0.000 description 34
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 26
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 22
- 150000005846 sugar alcohols Polymers 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 239000000469 ethanolic extract Substances 0.000 description 7
- 239000003673 groundwater Substances 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 244000013123 dwarf bean Species 0.000 description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 229940043375 1,5-pentanediol Drugs 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008096 Cerebral atrophy Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000012364 cultivation method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 229910052892 hornblende Inorganic materials 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000579185 Bucerotidae Species 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 241000266501 Ormosia ormondii Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
- -1 amino acid Amino acid Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- ZJHHPAUQMCHPRB-UHFFFAOYSA-N urea urea Chemical compound NC(N)=O.NC(N)=O ZJHHPAUQMCHPRB-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G31/00—Soilless cultivation, e.g. hydroponics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/60—Drinks from legumes, e.g. lupine drinks
- A23L11/65—Soy drinks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/70—Germinated pulse products, e.g. from soy bean sprouts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Mycology (AREA)
- Environmental Sciences (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 콩나물을 이용한 숙취해소음료 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 용존산소의 농도를 높인 물로 재배한 콩나물에 헛개나무 열매와 솔잎을 혼합하여 추출한 복합추출물을 함유하여 숙취해소 효과가 우수한 숙취해소음료 및 이의 제조방법에 관한 것이다.
본 발명의 콩나물을 이용한 숙취해소음료는 콩나물 추출물에 헛개나무 열매와, 솔잎을 혼합한 혼합물로부터 추출한 복합추출물을 함유하는 것을 특징으로 한다. The present invention relates to a hangover-free beverage using bean sprouts and a method for producing the same, and more particularly, to a bean sprout cultivated with water having a high concentration of dissolved oxygen, which contains a combination extract of Hovenia dulcis And to a process for producing the same.
The hangover-eliminating beverage using the bean sprouts of the present invention is characterized in that the bean sprouts extract contains a complex extract obtained by extracting a mixture of hovenous fruit and pine needle.
Description
본 발명은 콩나물을 이용한 숙취해소음료 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 용존산소의 농도를 높인 물로 재배한 콩나물에 헛개나무 열매와 솔잎을 혼합하여 추출한 복합추출물을 함유하여 숙취해소 효과가 우수한 숙취해소음료 및 이의 제조방법에 관한 것이다. The present invention relates to a hangover-eliminating beverage using bean sprouts and a method for producing the same, and more particularly, to a bean sprout cultivated with water having a high concentration of dissolved oxygen, which contains a combination extract of Hovenia dulcis And to a process for producing the same.
알코올은 뇌의 중추를 억제, 마비시켜 섭취시 외관상 흥분한 상태를 보여주게 되는데, 의식과 동작을 억제하고 수면 및 마취 효과가 있어 스트레스를 많이 받는 현대인의 기호식품으로 자리 잡고 있다. 우리 나라의 음주문화는 경제성장과 함께 경제활동을 위한 사교에서도 큰 몫을 담당할 뿐 아니라, 현대사회로부터 오는 정신적 외로움을 달래는 문화 생활의 일부가 되고 있다.Alcohol suppresses the central pace of the brain, and when it is paralyzed, it becomes apparently excited. It is a modern food which is stressful because it suppresses consciousness and movement and has sleep and anesthetic effect. Along with economic growth, drinking culture in our country is not only a part of social activities for economic activities, but also a part of cultural life to alleviate mental loneliness from modern society.
이처럼 술은 소량 섭취하면 기분전환을 위해서도 좋고 혈액순환에도 도움이 되어 건강에 유익할 수 있으나 과량을 만성적으로 섭취하면 알코올성 간질환 등 여러 가지 건강문제를 야기하게 되며, 중독증으로까지 발전할 수 있으며, 뇌 등의 중추신경계뿐 아니라 소화기관 및 간 등의 대사기관도 손상시킬 수 있어 개인의 건강을 위협하는 심각한 문제가 되고 있다. 또한, 음주로부터 비롯되는 교통사고 등의 위험은 개개인의 문제를 떠나서 사회적 문제로 되고 있으며, 이에 따라 알코올이 인체에 미치는 영향을 최소화할 수 있는 식품이나 의약품 등에 대한 요구도 증가하고 있다.As such, alcohol intake is good for diversion and blood circulation can be beneficial to health, but excessive intake of chronic intake of alcoholic liver disease and other health problems, can be developed to addiction, The central nervous system such as the brain, as well as the digestive organs and metabolic organs such as liver can damage the health of the individual is becoming a serious problem. In addition, the risk of traffic accidents resulting from drinking is becoming a social problem apart from individual problems, and the demand for foods and medicines that can minimize the impact of alcohol on the human body is also increasing.
술을 마시면, 알코올은 식도에서 소량 흡수되고 약 10%는 위장에서 90%는 소장에서 흡수되며, 흡수된 알코올은 혈류를 따라 뇌와 간 등 신체 각 조직으로 이동하며 약 10% 정도는 소변 및 땀으로 배출되고 나머지 90%는 간에서 분해된다. When you drink alcohol, alcohol is absorbed in the esophagus in a small amount, about 10% in the stomach, 90% in the small intestine, absorbed alcohol flows along the bloodstream to the brain, liver and other tissues of the body, about 10% And the remaining 90% is degraded in the liver.
알코올 분해의 첫 단계는, 알코올분해효소(alcohol dehydrogenase, ADH)가 알코올을 산화하여 아세트알데하이드로 전환시키며, 이는 다시 아세트알데하이드분해효소(aldehyde dehydrogenase, ALDH)에 의해 산화되어 신체에 무해한 초산으로 전환시킨다. 이 초산은 다시 물과 이산화탄소로 분해되어 체외로 배출된다. 각 단계에서 산화된 NAD+ 로부터 1분자의 환원형 NADH가 생성되며, 여기서 NAD+는 조효소의 역할을 한다. 간의 알코올 탈수소효소에 의한 알코올의 대사는 그 부산물로 NADH를 생성하여 NADH/NAD+ 비를 증가시킨다. 이러한 산화환원 상태의 변화는 여러 중간단계 대사에 영향을 미치게 된다. The first step in alcohol degradation is the conversion of alcohol dehydrogenase (ADH) to alcohol by oxidation to acetaldehyde, which in turn is oxidized by acetaldehyde dehydrogenase (ALDH) and converted to acetic acid, which is harmless to the body . This acetic acid is decomposed again into water and carbon dioxide and discharged to the outside of the body. At each step, one molecule of reduced NADH is produced from oxidized NAD +, where NAD + acts as a coenzyme. Alcohol metabolism by alcohol dehydrogenase in the liver produces NADH as a by-product and increases the NADH / NAD + ratio. This change in redox state affects several intermediate levels of metabolism.
특히, 젖산은 피루브산으로의 전환시 NAD+를 이용해야 하나 알코올 산화에 NAD+가 쓰이므로 젖산이 피루브산으로 전환되지 않고 축적되어 혈액의 pH를 떨어뜨린다. 뿐만 아니라 알코올 산화시 NADH/NAD+ 비가 증가되지만 계속적인 알코올의 산화를 위해서는 이들 비율을 정상적으로 유지시키는 것이 필요하다. 따라서 피루브산을 젖산으로 TCA 회로 내의 옥살로아세트산을 말산으로 전환시켜 이때 생성된 NAD+를 이용한다. 이러한 피루브산이나 옥살로아세트산의 부족은 포도당신생과정을 저해하여 포도당 합성이 제대로 이루어지지 못하게 하여 공복시 알코올을 섭취하면 저혈당을 초래할 수가 있다.In particular, lactic acid should use NAD + for conversion to pyruvic acid, but since NAD + is used for alcohol oxidation, lactic acid is not converted to pyruvic acid and accumulates to lower the pH of the blood. In addition, although the NADH / NAD + ratio increases during alcohol oxidation, it is necessary to maintain these ratios normally for the continuous oxidation of alcohol. Thus, pyruvic acid is converted to lactic acid by oxalacetic acid in the TCA circuit to lactic acid, and NAD + produced at this time is used. These deficiencies of pyruvic acid and oxaloacetic acid may interfere with the glucose neogenesis process, leading to poor glucose synthesis, which can lead to hypoglycemia when fasting alcohol is consumed.
알코올 섭취 후 나타나는 숙취 증상은 알코올 분해의 부산물인 아세트알데하이드가 분해되지 않고 오래 머물게 되면서 불쾌감, 두통, 혈압상승, 홍조, 구토 등을 유발시키는 것으로 알려져 있다. The symptoms of hangover after alcohol consumption are known to cause discomfort, headache, elevated blood pressure, flushing, and vomiting as acetaldehyde, a byproduct of alcohol decomposition, does not decompose.
대뇌와 간에 아세트알데하이드가 머무는 시간이 길어지면 신경계의 손상과 심각한 간질환이 유발되며 중추신경계이상 간성뇌장애, 대뇌위축, 알코올성 망막이상, 알코올 중독, 불안, 초조, 우울증, 수면장애, 알코올성 치매, 환청, 환시 등 심각한 신체적 문제를 발생된다.Acetaldehyde's long stay in the cerebrum and liver can lead to damage to the nervous system and serious liver disease. Cerebral atrophy, cerebral atrophy, alcoholic retinopathy, alcoholism, anxiety, irritability, depression, sleep disorders, alcoholic dementia, It causes serious physical problems such as hallucination, hallucination, and so on.
이와 같은 숙취 증상을 감소시킬 수 있는 약물에 대한 연구는 활발히 이루어져 이미 많은 제품이 소개되어 있다. 국내에서 시판되고 있는 숙취해소용 제제로는 컨디션(제일제당), 아스파(대상), 솔표비지니스(조선무약), 여명808(그래미), 리셉션(미래바이오), 모닝케어(동아제약) 등이 있다.Drugs that can reduce such hangover symptoms have been actively studied and many products have already been introduced. There are various kinds of drugs for hangovers that are marketed in Korea such as Condition (Cheil Jedang), Aspa (Target), Solpyo Business (Korean shipbuilding), Daehan 808 (Grammy), Reception (Future Bio), Morning Care .
그리고 특허 기술로 콩나물 추출물을 이용한 다수의 숙취해소음료가 개시되어 있다. A number of hangover-free beverages using a bean sprouts extract as a patented technology have been disclosed.
대한민국 공개특허 제2004-0005545호에는 숙취해소음료의 제조방법이 개시되어 있고, 공개특허 제 2006-0087323호에는 콩나물을 주원료로 한 콩나물음료의 제조방법이 개시되어 있고, 등록특허 제0989869호에는 콩나물 발효액을 함유하는 숙취해소음료가 개시되어 있다. Korean Patent Laid-Open No. 2004-0005545 discloses a method for producing hangover-free beverages, and Japanese Patent Laid-Open Publication No. 2006-0087323 discloses a method for producing bean sprouts beverage based on bean sprouts. In the patent No. 0989869, A hangover-eliminating beverage containing a fermentation liquid is disclosed.
하지만, 상기 개시된 숙취해소음료는 통상적인 재배방법으로 재배된 콩나물을 이용하므로 숙취해소 효과가 높지 않다는 문제점이 있다. However, since the bean sprouts cultivated by the conventional cultivation method are used for the hangover-eliminating beverage, there is a problem that the hangover resolution effect is not high.
본 발명은 상기의 문제점을 개선하고자 창출된 것으로서, 용존산소의 농도를 높인 물로 재배한 콩나물에 헛개나무 열매와 솔잎을 혼합하여 추출한 복합추출물을 함유함으로써 숙취해소 효과 및 기호도가 우수한 숙취해소음료 및 이의 제조방법을 제공하는 데 그 목적이 있다. The present invention has been made in order to overcome the above problems, and it is an object of the present invention to provide a bean sprout which is grown with water having a high concentration of dissolved oxygen and a combination extract of Hovenia dulcis And a manufacturing method thereof.
상기의 목적을 달성하기 위한 본 발명의 콩나물을 이용한 숙취해소음료는 콩나물 추출물에 헛개나무 열매와 솔잎을 혼합한 혼합물로부터 추출한 복합추출물을 함유하는 것을 특징으로 한다. In order to achieve the above object, the hangover-eliminating beverage using the bean sprouts according to the present invention is characterized in that the bean sprouts extract contains a complex extract derived from a mixture of Hovenia dulcis var.
상기 콩나물 추출물은 콩나물과 올리고당을 혼합한 후 1 내지 3일간 재운 다음 콩나물을 제거하여 수득한 것을 특징으로 한다. The bean sprouts extract is characterized in that bean sprouts are mixed with oligosaccharides and then laid for 1 to 3 days, followed by removal of bean sprouts.
상기 콩나물은 재배수의 용존산소 농도를 10 내지 20ppm으로 조절하여 재배한 것을 특징으로 한다. The bean sprouts are cultivated by adjusting the dissolved oxygen concentration of the cultivated water to 10 to 20 ppm.
상기 콩나물은 머리가 녹색인 녹색 콩나물인 것을 특징으로 한다. The bean sprouts are green bean sprouts whose heads are green.
상기의 목적을 달성하기 위한 본 발명의 콩나물을 이용한 숙취해소음료의 제조방법은 콩을 발아시킨 후 재배수를 공급하여 콩나물을 재배하는 재배단계와; 상기 콩나물로부터 콩나물 추출물을 추출하는 제 1추출단계와; 상기 콩나물 추출물 에 헛개나무 열매와 솔잎을 혼합하여 혼합물을 수득하는 혼합단계와; 상기 혼합물에 추출용매를 가해 복합추출물을 추출하는 제 2추출단계와; 상기 복합추출물에 물을 가하여 희석시키는 제형단계;를 포함하는 것을 특징으로 한다. To achieve the above object, there is provided a method for producing a hangover-free beverage using bean sprouts according to the present invention, comprising: culturing bean sprouts by cultivating soybeans and supplying cultivation water; A first extraction step of extracting a bean sprouts extract from the bean sprouts; Mixing the bean sprouts extract with hornblende and pine leaves to obtain a mixture; A second extraction step of extracting the complex extract by adding an extraction solvent to the mixture; And a step of diluting the complex extract with water.
상기 재배단계는 용존산소 농도를 10 내지 20ppm으로 조절한 상기 재배수를 2 내지 6시간 간격으로 5 내지 15분씩 살수하여 재배하는 것을 특징으로 한다. The cultivation step is characterized in that the cultivated water having the dissolved oxygen concentration adjusted to 10 to 20 ppm is sprinkled for 5 to 15 minutes every 2 to 6 hours.
상기 재배단계는 a)발아된 콩을 재배용기에 넣고 20 내지 30℃의 암실에서 재배수를 2 내지 6시간 간격으로 5 내지 15분씩 살수하여 5 ~ 7일간 1차 재배하는 단계와, b)상기 1차 재배된 콩나물에 적색광을 조사하여 2 내지 4일간 2차 재배하는 단계로 이루어진 것을 특징으로 한다. Wherein the cultivation step comprises: a) placing the germinated soybeans in a cultivation vessel, cultivating the cultivated water in a dark room at 20 to 30 캜 for 5 to 15 minutes at intervals of 2 to 6 hours, and then primary culturing for 5 to 7 days; and b) And then cultivating the bean sprouts firstly cultivated with red light for 2 to 4 days.
상술한 바와 같이 본 발명은 콩나물, 헛개열매, 솔잎의 복합추출물을 함유하여 간 보호 및 숙취해소 효과가 우수하여 숙취해소음료로 유용하게 활용될 수 있다. As described above, the present invention contains a combined extract of bean sprouts, hut fruit and pine leaves, and is excellent in liver protection and hangover relieving effect, and thus can be usefully used as a hangover-free beverage.
그리고 용존산소의 농도를 높인 물로 재배한 콩나물로부터 추출한 콩나물 추출물을 이용할 경우 간 보호 및 숙취해소 효과를 더욱 향상시킬 수 있다. And the use of bean sprouts extract extracted from bean sprouts grown with water with a higher concentration of dissolved oxygen can further improve the effect of preventing liver and hangover.
도 1 및 2는 과산화수소 처리에 의한 HepG2 세포의 생존율을 나타낸 그래프이다. 1 and 2 are graphs showing the survival rate of HepG2 cells by hydrogen peroxide treatment.
이하, 본 발명의 바람직한 실시 예에 따른 콩나물을 이용한 숙취해소음료 및 이의 제조방법에 대하여 구체적으로 설명한다. Hereinafter, a hangover-eliminating beverage using bean sprouts according to a preferred embodiment of the present invention and a method of producing the hangover-free beverage will be described in detail.
본 발명의 일 실시 예에 따른 숙취해소음료는 복합추출물을 함유한다. 복합추출물은 콩나물 추출물에 헛개나무 열매와 솔잎을 혼합한 혼합물로부터 추출한다. 혼합물은 일 예로 콩나물 추출물 100중량부에 대하여 헛개나무 열매 0.1 내지 20중량부와, 솔잎 0.1 내지 20중량부를 혼합하여 조성할 수 있다. 조성된 혼합물에 추출용매를 가해 복합추출물을 추출한다. The hangover-eliminating beverage according to one embodiment of the present invention contains a complex extract. The compound extract is extracted from the mixture of the hornblende and the pine needle with the bean sprouts extract. For example, the mixture may be prepared by mixing 0.1 to 20 parts by weight of Hovenia dulcis and 0.1 to 20 parts by weight of pine needle per 100 parts by weight of the bean sprouts extract. The resulting mixture is extracted with an extraction solvent.
헛개나무 열매와 솔잎은 콩나물 추출물과 더해져 음료의 숙취해소 효과를 향상시키며 영양성분을 강화시킨다.Hovenia fruit and pine needles are added with bean sprouts extract to improve the hangover effect of beverages and enhance nutritional components.
본 발명에서 콩나물 추출물은 다양한 방법으로 추출이 가능하다. 통상적인 방법으로 콩나물에 추출용매를 가하여 추출할 수 있다. 추출용매로 물, 탄소수 1 내지 4의 저급 알코올, 다가 알코올 또는 이들의 혼합용매로부터 선택된 적어도 어느 하나를 이용할 수 있다. 탄소수 1 내지 4의 저급 알코올로 메탄올, 에탄올 등을 이용할 수 있고, 다가 알코올로 부틸렌글리콜 및 프로필렌글리콜, 펜틸렌글리콜 등을 이용할 수 있다. 그리고 혼합용매로는 물 및 저급 알코올의 혼합물, 물 및 다가 알코올의 혼합물, 저급 알코올 및 다가 알코올의 혼합물, 또는 물 및 저급알코올 및 다가 알코올의 혼합물을 이용할 수 있다. In the present invention, the bean sprouts extract can be extracted by various methods. Extraction solvent can be added to bean sprouts by a conventional method. As the extraction solvent, at least one selected from water, a lower alcohol having 1 to 4 carbon atoms, a polyhydric alcohol, or a mixed solvent thereof may be used. As the lower alcohol having 1 to 4 carbon atoms, methanol, ethanol and the like can be used. As the polyhydric alcohol, butylene glycol, propylene glycol, pentylene glycol and the like can be used. As the mixed solvent, a mixture of water and a lower alcohol, a mixture of water and a polyhydric alcohol, a mixture of a lower alcohol and a polyhydric alcohol, or a mixture of water and a lower alcohol and a polyhydric alcohol can be used.
콩나물 추출물의 일 예로 콩나물에 대하여 추출용매를 중량비로 2 내지 20배를 가한 후 10 내지 150℃에서 1 내지 24시간 동안 열수추출, 냉침 또는 온침 추출 등을 이용하여 추출한 후 여과하여 얻을 수 있다. As an example of the bean sprouts extract, extracting the bean sprouts with hot water extraction, cold extraction or warm-up extraction at 10 to 150 ° C for 1 to 24 hours after adding 2 to 20 times the weight of the extraction solvent, and filtering the bean sprouts.
또한, 상술한 통상적인 추출방법과 달리 올리고당을 이용하여 콩나물 추출물을 추출할 수 있다. 예를 들어 콩나물 100부피부에 대하여 올리고당 100 내지 300부피부를 혼합한 후 15 내지 25℃의 실온에서 1 내지 3일간 재운 다음 콩나물만을 제거하여 콩나물 추출물을 수득할 수 있다. 여기서 콩나물 추출물은 콩나물이 제거된 올리고당이다. 콩나물을 올리고당에 재우면 콩나물의 유용성분들과 수분이 올리고당으로 배출된다. 이와 같이 콩나물을 올리고당을 이용하여 추출하게 되면 낮은 온도에서도 콩나물의 유용성분들을 용이하게 추출할 수 있으며, 별도의 감미료를 첨가하지 않아도 음료의 적절한 당도를 유지할 수 있다. Unlike the conventional extraction method, soybean sprout extract can be extracted using oligosaccharide. For example, 100 parts of bean sprouts may be mixed with 100-300 parts of oligosaccharide, and the bean sprouts may be obtained by removing only the bean sprouts from the mixture at room temperature of 15 to 25 DEG C for 1 to 3 days. Here, the bean sprouts extract is an oligosaccharide from which bean sprouts are removed. When bean sprouts are placed on oligosaccharides, the usefulness of bean sprouts and moisture are released into oligosaccharides. When bean sprouts are extracted using oligosaccharides, the bean sprouts useful in bean sprouts can be easily extracted even at low temperatures, and the proper sugar content of the beverage can be maintained without adding any additional sweetener.
주재료인 콩나물은 통상적인 방법으로 재배한 콩나물을 사용할 수 있지만, 바람직하게 용존산소 농도를 10 내지 20ppm으로 조절한 재배수를 공급하여 재배한 콩나물을 사용한다. 통상적인 지하수나 상수에 비해 용존산소의 농도를 높인 재배수로 재배한 콩나물은 숙취해소효과를 향상시킬 수 있다. The bean sprouts used as the main material may be bean sprouts grown by a conventional method, but bean sprouts cultivated by supplying cultured water with a dissolved oxygen concentration of preferably 10 to 20 ppm are preferably used. Soybean sprouts grown with cultivated water with a higher concentration of dissolved oxygen than conventional ground water or water can improve the hangover resolution effect.
또한, 콩나물은 머리가 녹색인 녹색 콩나물을 이용할 수 있다. 녹색 콩나물을 숙취해소 음료의 기능성을 강화시킬 수 있다. In addition, bean sprouts can use green bean sprouts whose heads are green. It is possible to enhance the functionality of the green bean sprouts hangover drink.
본 발명의 숙취해소음료는 상기 복합추출물을 음료 전체 중량에서 20 내지 90중량%를 함유한다. 가령, 숙취해소음료는 복합추출물 20 내지 90중량%, 물 10 내지 80중량%로 조성될 수 있다. The hangover-eliminating beverage of the present invention contains 20 to 90% by weight of the combined extract in the total weight of the beverage. For example, the hangover-resolved beverage may be composed of 20 to 90% by weight of the combined extract and 10 to 80% by weight of water.
또한, 본 발명의 숙취해소음료에는 식품학적으로 허용 가능한 공지의 첨가물이 첨가될 수 있음은 물론이다. 첨가물로 타우린, 구연산, 비타민C, 탄수화물 등을 예로 들 수 있다. 상기 탄수화물은 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등이다. 이외에도 통상의 음료와 같이 여러 가지 향미제가 추가 성분으로서 함유될 수 있다. 향미제로서 타우마틴, 스테비아 추출물 등의 천연 향미제를 사용할 수 있다. It is needless to say that the hangover-free beverage of the present invention may contain known additives which are pharmaceutically acceptable. Examples of additives include taurine, citric acid, vitamin C, and carbohydrates. The carbohydrate may be a monosaccharide such as glucose, fructose, etc .; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and xylitol, sorbitol, erythritol, and the like. In addition, various flavorings such as ordinary beverages may be contained as additional ingredients. Natural flavoring agents such as tau martin and stevia extract can be used as flavorings.
이하, 본 발명의 콩나물을 이용한 숙취해소음료의 제조방법에 대하여 설명한다. Hereinafter, a method for producing a hangover-free beverage using the bean sprouts according to the present invention will be described.
본 발명의 숙취해소음료의 제조방법은 재배수를 공급하여 콩나물을 재배하는 재배단계와, 재배한 콩나물과 올리고당을 혼합하여 재운 다음 콩나물을 제거하여 콩나물 추출물을 수득하는 제 1추출단계와, 콩나물 추출물에 헛개나무 열매와 솔잎을 혼합하여 혼합물을 수득하는 혼합단계와, 혼합물에 추출용매를 가해 복합추출물을 추출하는 제 2추출단계와, 복합추출물에 물을 가하여 희석시키는 제형단계를 포함한다. 단계별로 구체적으로 살펴본다.A method for producing a hangover-resolved beverage according to the present invention comprises: a cultivation step of cultivating soybean sprouts by supplying cultivated water; a first extracting step of mixing soybean sprouts and oligosaccharides cultivated and removing soybean sprouts to obtain soybean sprouts; A second extraction step of extracting the complex extract by adding an extraction solvent to the mixture, and a step of diluting the complex extract by adding water to the mixture. We will look at each step in detail.
1. 재배단계1. Growth stage
먼저, 콩을 발아시킨 후 재배수를 공급하여 콩나물을 재배한다. 예를 들어, 콩을 물에 하루 정도 담가 불린 다음 20 내지 30℃에서 방치하여 발아시킨다. 그리고 발아된 콩을 통상적인 콩나물 재배용기에 넣고 20 내지 30℃의 암실에서 재배수를 일정 주기로 살수하여 5 ~ 7일간 재배한다. 재배수는 2 내지 6시간 간격으로 5 내지 15분씩 살수할 수 있다. First, soybean is germinated and cultivated with soybean sprouts. For example, beans are soaked in water for one day and then germinated by standing at 20 to 30 ° C. Then, the germinated soybeans are placed in a conventional bean sprout cultivation vessel, cultivated in a dark room at 20 to 30 ° C for a period of 5 to 7 days. Cultivation water can be sprayed every 2 to 6 hours at 5 to 15 minutes.
바람직하게 재배수는 용존산소 농도를 10 내지 20ppm으로 조절한 것을 이용한다. 재배수로 지하수나 상수에 산소를 인위적으로 용해시켜 용존산소의 농도를 10 내지 20ppm으로 조절한 것을 이용한다. Preferably, the cultivated water has a dissolved oxygen concentration adjusted to 10 to 20 ppm. It is made by cultivating water by artificially dissolving oxygen in ground water or water and adjusting the concentration of dissolved oxygen to 10-20 ppm.
통상적인 콩나물 재배에 사용하는 지하수나 상수는 용존산소농도가 5 내지 7ppm인데 반해 본 발명에서 이용하는 재배수의 용존산소 농도는 10 내지 20ppm이다. 이와 같이 재배수의 용존산소의 농도를 높여 콩나물을 재배하는 경우 콩나물에 함유된 아스파라긴산의 함량을 높일 수 있어 숙취해소 효과를 향상시킬 수 있다. The concentration of dissolved oxygen in the cultivation water used in the present invention is 10 to 20 ppm, whereas the amount of dissolved oxygen in the groundwater or the constant used in conventional bean sprouts cultivation is 5 to 7 ppm. When soybean sprouts are grown by increasing the concentration of dissolved oxygen in the cultivated water, the content of aspartic acid contained in the soybean sprouts can be increased and the hangover resolution effect can be improved.
한편, 본 발명의 다른 실시 예에 따른 재배단계는 빛을 조사하지 않고 재배하는 1차 재배, 빛을 조사하여 재배하는 2차 재배로 과정을 나눌 수 있다. Meanwhile, the cultivation step according to another embodiment of the present invention can be divided into a first cultivation without light irradiation, and a second cultivation with light irradiation.
1차 재배는 상술한 재배방법과 동일하다. 즉, 발아된 콩을 재배용기에 넣고 20 내지 30℃의 암실에서 재배수를 2 내지 6시간 간격으로 5 내지 15분씩 살수하여 5 ~ 7일간 1차 재배한다. 1차 재배시 재배수로 통상적인 지하수나 상수를 이용할 수 있지만, 바람직하게 산소를 인위적으로 용해시켜 용존산소의 농도를 10 내지 20ppm으로 조절한 것을 이용할 수 있다. The primary cultivation is the same as the cultivation method described above. That is, the germinated soybeans are placed in a cultivation vessel, cultivated in a dark room at 20 to 30 ° C for 5 to 15 minutes at intervals of 2 to 6 hours, and cultivated for 5 to 7 days. Conventional ground water or a constant water may be used as the cultivation water in the first cultivation, but it is preferable to use a solution in which oxygen is artificially dissolved to adjust the concentration of dissolved oxygen to 10 to 20 ppm.
2차 재배는 1차 재배된 콩나물에 빛을 조사하여 콩나물이 광합성을 할 수 있도록 한다. 2차 재배는 재배기간과 빛의 조사만을 제외하고는 1차 재배와 재배조건이 동일하다. 가령, 2차 재배는 암실에 적색광을 조사하여 콩나물을 2 내지 4일간 재배한다. 암실에 600~700nm 파장의 적생광을 발산하는 광원을 설치하여 콩나물을 재배한다. In the second cultivation, bean sprouts are cultivated for the first time, and light is irradiated to allow the bean sprouts to perform photosynthesis. The second cultivation is the same as the first cultivation and cultivation except for cultivation period and light irradiation. For example, in the second cultivation, soybean sprouts are grown for 2 to 4 days by irradiating the dark room with red light. A bean sprout is grown by installing a light source that emits red light of 600 ~ 700nm wavelength in the dark room.
2차 재배를 통해 콩나물 머리는 노랑색에서 녹색으로 바뀌면서 노랑색 콩나물이 갖지 못한 다양한 영양성분을 갖는다. 머리가 녹색인 녹색 콩나물은 각종 영양소가 풍부하여 숙취해소음료의 기능성을 강화시킬 수 있다. Through the second cultivation, the bean sprouts are changed from yellow to green, and have various nutritional components which do not have yellow bean sprouts. Green bean sprouts with green hair are rich in various nutrients, which can enhance the functionality of hangover-free beverages.
2. 제 1추출단계2. First extraction step
콩나물을 재배한 후 수확한다. 수확한 콩나물을 물로 깨끗이 세척한 후 물기를 제거하여 준비한다.Bean sprouts are grown and harvested. Wash the harvested bean sprouts thoroughly with water and remove the water.
콩나물 추출물은 다양한 방법으로 추출이 가능하다. 통상적인 방법으로 콩나물에 추출용매를 가하여 추출할 수 있다. 추출용매로 물, 탄소수 1 내지 4의 저급 알코올, 다가 알코올 또는 이들의 혼합용매로부터 선택된 적어도 어느 하나를 이용할 수 있다. 탄소수 1 내지 4의 저급 알코올로 메탄올, 에탄올 등을 이용할 수 있고, 다가 알코올로 부틸렌글리콜 및 프로필렌글리콜, 펜틸렌글리콜 등을 이용할 수 있다. 그리고 혼합용매로는 물 및 저급 알코올의 혼합물, 물 및 다가 알코올의 혼합물, 저급 알코올 및 다가 알코올의 혼합물, 또는 물 및 저급알코올 및 다가 알코올의 혼합물을 이용할 수 있다. The bean sprouts extract can be extracted by various methods. Extraction solvent can be added to bean sprouts by a conventional method. As the extraction solvent, at least one selected from water, a lower alcohol having 1 to 4 carbon atoms, a polyhydric alcohol, or a mixed solvent thereof may be used. As the lower alcohol having 1 to 4 carbon atoms, methanol, ethanol and the like can be used. As the polyhydric alcohol, butylene glycol, propylene glycol, pentylene glycol and the like can be used. As the mixed solvent, a mixture of water and a lower alcohol, a mixture of water and a polyhydric alcohol, a mixture of a lower alcohol and a polyhydric alcohol, or a mixture of water and a lower alcohol and a polyhydric alcohol can be used.
콩나물 추출방법의 또 다른 예로 준비된 콩나물과 올리고당을 혼합한 후 1 내지 3일간 재운다. 콩나물 100부피부에 대하여 올리고당 100 내지 300부피부를 혼합한 후 15 내지 25℃의 실온에서 1 내지 3일간 재우면 콩나물의 유용성분들과 수분이 올리고당으로 배출된다. 콩나물과 올리고당을 혼합하여 1 내지 3일간 재운 후 콩나물만을 건져내어 콩나물 추출물을 수득한다. As another example of the method of extracting bean sprouts, the prepared bean sprouts are mixed with oligosaccharides and then put on for 1 to 3 days. 100 parts of
3. 혼합단계3. Mixing step
다음으로, 콩나물 추출물에 헛개나무 열매와 솔잎을 혼합하여 혼합물을 수득한다. 가령, 콩나물 추출물 100중량부에 대하여 헛개나무 열매 0.1 내지 20중량부와, 솔잎 0.1 내지 20중량부를 혼합할 수 있다. Next, to the bean sprouts extract, a mixture of Hovenous Fruit and pine leaves is obtained. For example, 0.1 to 20 parts by weight of Hovenia dulcis and 0.1 to 20 parts by weight of pine needle can be mixed with 100 parts by weight of the bean sprouts extract.
4. 제 2추출단계4. Second extraction step
콩나물 추출물, 헛개나무 열매, 솔잎이 혼합된 혼합물에 추출용매를 가해 복합추출물을 추출한다. Extracts are extracted from a mixture of bean sprouts, hornbills and pine leaves.
일 예로 혼합물에 대하여 추출용매를 중량비로 2 내지 20배를 가한 후 10 내지 150℃에서 1 내지 24시간 동안 열수추출, 냉침 또는 온침 추출 등을 이용하여 추출한 후 여과하여 복합추출물을 얻을 수 있다. 또한, 환류냉각추출, 초음파 추출방법, 초임계 유체 추출방법 등을 이용할 수 있다. 또한, 상술한 추출방법뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 일정한 분자량 컷-오프 값을 갖는 한외여과막을 이용한 분리, 다양한 크로마토그래피에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 추출물에 포함되는 것이다.For example, the extraction solvent may be extracted 2 to 20 times by weight of the extraction solvent at a temperature of 10 to 150 ° C for 1 to 24 hours using hot water extraction, cold-water extraction or warm-up extraction, followed by filtration to obtain a complex extract. In addition, a reflux cooling extraction, an ultrasonic extraction method, a supercritical fluid extraction method, or the like can be used. In addition to the above-described extraction method, an extract obtained through a conventional purification process is also included. For example, an active fraction obtained through various purification methods, such as separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatographies, etc., is also included in the extract.
추출용매로 물, 탄소수 1 내지 4의 저급 알코올, 다가 알코올 또는 이들의 혼합용매로부터 선택된 적어도 어느 하나를 이용할 수 있다. 탄소수 1 내지 4의 저급 알코올로 메탄올, 에탄올 등을 이용할 수 있고, 다가 알코올로 부틸렌글리콜 및 프로필렌글리콜, 펜틸렌글리콜 등을 이용할 수 있다. 그리고 혼합용매로는 물 및 저급 알코올의 혼합물, 물 및 다가 알코올의 혼합물, 저급 알코올 및 다가 알코올의 혼합물, 또는 물 및 저급알코올 및 다가 알코올의 혼합물을 이용할 수 있다. As the extraction solvent, at least one selected from water, a lower alcohol having 1 to 4 carbon atoms, a polyhydric alcohol, or a mixed solvent thereof may be used. As the lower alcohol having 1 to 4 carbon atoms, methanol, ethanol and the like can be used. As the polyhydric alcohol, butylene glycol, propylene glycol, pentylene glycol and the like can be used. As the mixed solvent, a mixture of water and a lower alcohol, a mixture of water and a polyhydric alcohol, a mixture of a lower alcohol and a polyhydric alcohol, or a mixture of water and a lower alcohol and a polyhydric alcohol can be used.
5. 제형단계5. Formulation step
제형단계에서 복합추출물에 물을 가하여 희석시킴으로써 본 발명의 숙취해소음료가 제조된다. 본 발명의 숙취해소음료는 복합추출물을 음료 전체 중량에서 20 내지 90중량%를 함유한다. 가령, 숙취해소음료는 제형단계에서 복합추출물 20 내지 90중량%, 물 10 내지 80중량%를 혼합하여 제조될 수 있다.The hangover-free beverage of the present invention is prepared by adding water to the complex extract in the formulating step and diluting it. The hangover-eliminating beverage of the present invention contains 20 to 90 wt% of the combined extract in the total weight of the beverage. For example, the hangover-free beverage may be prepared by mixing 20 to 90% by weight of the combined extract and 10 to 80% by weight of water in the formulation step.
또한, 제형단계에서 식품학적으로 허용 가능한 공지의 첨가물이 첨가될 수 있음은 물론이다. 첨가물로 타우린, 구연산, 비타민C, 탄수화물 등을 예로 들 수 있다. In addition, it is a matter of course that known additives which are pharmaceutically acceptable in the formulating step can be added. Examples of additives include taurine, citric acid, vitamin C, and carbohydrates.
이하, 본 발명의 이해를 돕기 위하여 실시 예를 제시하나, 하기 실시 예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시 예에 한정되는 것은 아니다.EXAMPLES Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following examples.
<콩나물 추출물의 제조><Preparation of bean sprouts extract>
재배수의 용존산소농도를 달리하여 콩나물을 재배하였다. 발아시킨 콩나물용 콩을 통상적인 콩나물 재배용기에 넣고 25℃의 암실에서 6일간 재배하였다. 재배기간 동안 재배수는 4시간 간격으로 10분씩 재배용기에 살수하였다. Soybean sprouts were cultivated by varying dissolved oxygen concentration in cultivated water. The bean sprouts were germinated into a conventional bean sprout cultivation vessel and grown in a dark room at 25 ° C for 6 days. During the cultivation period, the cultivated water was distributed in the cultivation vessel for 10 minutes every 4 hours.
재배수로 용존산소농도 6ppm인 지하수(이하, 일반수)와 용존산소농도를 높인 산소수를 이용하였다. 산소수는 산소용해기를 이용하여 지하수의 용존산소농도를 10, 15, 20ppm으로 조절하였다. Groundwater (DOE), which has a dissolved oxygen concentration of 6ppm (hereafter referred to as general water), and oxygen water with a higher dissolved oxygen concentration were used as cultivated water. The dissolved oxygen concentration of ground water was adjusted to 10, 15, and 20 ppm using oxygen dissolver.
지하수와 산소수로 재배한 콩나물을 수확하여 물로 깨끗이 세척한 다음 추출용매를 가하여 추출하였다. 추출용매로 물과 70% 에탄올을 이용하여 열수추출물과 에탄올추출물을 각각 추출하였다. The bean sprouts cultivated with ground water and oxygenated water were harvested, washed thoroughly with water, and extracted with an extraction solvent. Extracts of hot water and ethanol were extracted with water and 70% ethanol.
열수추출물의 경우 콩나물에 물을 중량비로 8배를 가한 후 100℃에서 6시간 동안 추출한 다음 여과하여 준비하였다. 그리고 에탄올추출물의 경우 콩나물에 70% 에탄올을 중량비로 10배를 가한 후 40℃에서 200rpm으로 교반시키면서 12시간 동안 추출한 다음 여과하고 45℃에서 20분 동안 감압농축하여 준비하였다. In the case of the hot-water extract, water was added to the bean sprouts 8 times at a weight ratio, and then the mixture was extracted at 100 ° C for 6 hours and then filtered. In the case of the ethanol extract, 70% ethanol was added to the bean sprouts at a weight ratio of 10 times, and the mixture was stirred at 40 ° C and 200 rpm for 12 hours, filtered and concentrated under reduced pressure at 45 ° C for 20 minutes.
일반수로 재배하여 수확한 콩나물의 열수추출물과 에탄올추출물을 각각 일반수 열수추추물과 일반수 에탄올 추출물, 산소수로 재배하여 수확한 콩나물의 열수추출물과 에탄올추출물을 각각 산소수 열수추출물과 산소수 에탄올추출물로 구분하였다. The hot and cold water extracts and ethanol extracts of soybean sprouts harvested from ordinary hot - water extracts, ordinary water ethanol extracts, and oxygenated water were added to hot water extracts and oxygenated water Ethanol extracts.
<재배조건에 따른 콩나물 추출물의 세포실험><Cell culture of bean sprouts extract according to growing conditions>
실험에서 사용된 HepG2 세포는 인간 간세포 유래의 배양세포로서, 약물과 영양분에 대하여 인간 간세포에서 이루어지고 있는 것과 동일한 양상을 나타낸다고 알려져 있어 사람의 간장에서의 대사를 연구하는데 적절한 모델 세포로서 다양하게 연구가 진행되고 있다. The HepG2 cells used in the experiment are cultured cells derived from human hepatocytes, and they are known to exhibit the same pattern as that of human hepatocytes for drugs and nutrients. Therefore, various studies have been conducted as model cells suitable for studying metabolism in human liver It is progressing.
따라서 본 실험에서는 HepG2 세포를 이용하여 과산화수소로 인한 산화적 스트레스성 간 손상에 있어서 콩나물 추출물의 효과를 검토하고자 하였다. Therefore, in this experiment, we investigated the effect of soybean sprout extract on the oxidative stress - induced liver injury caused by hydrogen peroxide using HepG2 cells.
1. HepG2 세포주 배양1. HepG2 cell line culture
HepG2 cell line의 배지는 10%(v/v) FBS(fetal bovine serum), 0.5%(v/v), 50 g/ml streptomycin, 50 IU/ml penicillin, 0.125 g/ml fungizone, 3.024 g sodium bicarbonate를 함유한 Minimal Essential Medium(MEM)을 사용하였고, 배양은 37℃, 5% CO2, 95% humid air로 조절된 배양기를 사용하였다. 배지는 2일마다 교환하였으며, confluency가 80% 되었을 때 subculture를 실시하였다.The HepG2 cell line medium consisted of 10% (v / v) fetal bovine serum, 0.5% v / v, 50 g / ml streptomycin, 50 IU / ml penicillin, 0.125 g / ml fungizone, (MEM) medium containing 5% CO 2 and 95% humidified air at 37 ° C was used. The medium was changed every 2 days and subculture was performed when confluency was 80%.
2. 콩나물 추출물의 항산화 스트레스 간 손상 억제능 탐색2. Detection of Antioxidative Stress Liver Damage by Soybean Sprouts Extract
HepG2 세포주를 24 well plate에 5 × 104 cells/well로 분주한 후 각 well에 시료가 포함된 혈청(serum)을 3% 함유한 배지를 첨가하고 24시간 동안 37℃ 배양기에서 반응시켰다. 그리고 PBS로 세척 후 과산화수소를 처리한 다음 24시간 동안 배양기 반응 후 배지를 제거하고 XTT-PMS 용액을 넣어 2시간 동안 반응시켰다. 그 후 생성된 포마즌(formazan)을 microplate reader를 사용하여 450nm에서 흡광도를 측정하였다. 음성 대조구(Cont.)는 시료 대신 media만을 사용하였으며, 양성 대조구로는 0.3mM 과산화수소만을 처리하였다.The HepG2 cell line was dispensed into a 24-well plate at 5 × 10 4 cells / well. Then, a medium containing 3% of serum containing the sample was added to each well and reacted in a 37 ° C. incubator for 24 hours. After washing with PBS, the cells were treated with hydrogen peroxide. After incubation for 24 hours, the medium was removed and XTT-PMS solution was added for 2 hours. The resulting formazan was measured for absorbance at 450 nm using a microplate reader. Negative control (Cont.) Was used only media instead of sample, and positive control was treated with 0.3 mM hydrogen peroxide only.
세포손상은 formazan의 형성 정도를 450nm에서 흡광도를 측정한 후, 시료 대신 media만 첨가한 음성 대조군의 흡광도를 세포 생존율 100%로 설정하여 그에 따른 상대적인 흡광도를 세포 생존율(%)로 계산하여 도 1에 그 결과를 나타내었다. The degree of cell damage was determined by measuring the absorbance at 450 nm for the degree of formation of formazan, setting the absorbance of the negative control added with medium instead of the sample as 100%, and calculating the relative absorbance as a cell survival rate (%) as shown in FIG. The results are shown.
도 1에서 cont.: 음성대조구, H2O2 : 0.3mM 과산화수소, CA40 : positive control caffeic acid 40ug/mL, 산소수 water : 0.3mM 과산화수소 + 산소수(15ppm) 열수추출물(100, 300㎍/mL), 일반수 water : 0.3mM 과산화수소 + 일반수 열수추출물(100, 300㎍/mL), 산소수 EtOH : 0.3mM 과산화수소 + 산소수(15ppm) 에탄올추출물(100, 300㎍/mL), EtOH 일반수 : 0.3mM 과산화수소 + 일반수 에탄올추출물(100, 300㎍/mL)이다. (100 ppm, 300 μg / mL), normal control caffeic acid (40 μg / mL), oxygenated water (0.3 ppm) and hydrogen peroxide (100, 300 / / mL), water (0.3 mM) Hydrogen peroxide + water (100, 300 / / mL), oxygen water EtOH: 0.3 mM Hydrogen peroxide + oxygen water (15 ppm) Ethanol extract Hydrogen peroxide + normal water ethanol extract (100, 300 / / mL).
도 1을 참조하면, 과산화수소 처리로 유도된 산화적 스트레스로 인해 세포들의 생존률이 크게 낮아졌다. 그리고 과산화수소에 의한 세포손상은 콩나물 추출물의 처리에 의해 감소된 것으로 확인되었다. 특히, 산소수 열수추출물은 일반수 열수추출물에 비해 거의 100%에 가까운 세포 생존율을 보였다. 이는 산소의 농도를 높여 재배한 콩나물로부터 추출한 열수추출물이 과산화수소에 의한 간세포 손상에 대해 우수한 보호효과가 있음을 보여주는 결과이다. Referring to FIG. 1, the oxidative stress induced by the hydrogen peroxide treatment greatly reduced the survival rate of the cells. And it was confirmed that the cell damage caused by hydrogen peroxide was reduced by the treatment of bean sprouts extract. In particular, the oxygenated hydrothermal extract showed cell viability close to 100% as compared with the general hydrothermal extract. This result shows that the hydrothermal extracts from soybean sprouts grown by increasing the oxygen concentration have excellent protection against hepatocyte injury by hydrogen peroxide.
열수추출물이 에탄올추출물에 비해 간 손상 억제 효과가 더 우수한 것으로 판단되어 열수추출물을 이용하여 추가적으로 실험을 더 진행하였다. The hydrothermal extracts were superior to ethanol extracts in inhibiting liver damage, and further experiments were conducted using hot water extracts.
실험방법은 상술한 실험과 동일하게 진행하였고, 열수추출물로 일반수 열수추출물, 산소수(10ppm, 20ppm) 열수추출물을 이용하였다. The experiment was carried out in the same manner as the above experiment. As a hot water extract, hot water extract of ordinary water and oxygenated water (10 ppm, 20 ppm) were used.
실험결과를 도 2에 나타내었다. 도 2에서 control : 음성대조구, H2O2 : 0.3mM 과산화수소, 고산소: 0.3mM 과산화수소 + 산소수(20ppm) 열수추출물(100, 300㎍/mL), 일반수: 0.3mM 과산화수소 + 일반수 열수추출물(100, 300㎍/mL), 저산소: 0.3mM 과산화수소 + 산소수(10ppm) 열수추출물(100, 300㎍/mL)이다. The experimental results are shown in Fig. In FIG. 2, control: negative control, H2O2: 0.3mM hydrogen peroxide, high oxygen: 0.3mM hydrogen peroxide + oxygen water (20ppm) hot water extract (100, 300g / , 300 μg / mL), hypoxic: 0.3 mM hydrogen peroxide + oxygenated water (10 ppm), hot water extract (100, 300 μg / mL)
도 2를 참조하면, 산소수 열수추출물이 간세포 손상에 대하여 보호효과가 다소 있는 것으로 나타났다. 특히, 10ppm 농도의 용존산소에서 재배한 콩나물로부터 추출한 열수추출물을 300 ㎍/mL 처리하였을 때 유의적인 차이를 나타내었다. Referring to FIG. 2, it was found that the extract of oxygenated hydrothermal solution had a somewhat protective effect against hepatocyte injury. Especially, when 300 ㎍ / mL of hot water extract extracted from soybean sprouts cultivated at 10 ppm concentration of dissolved oxygen was treated, significant difference was shown.
<아미노산 분석><Amino acid analysis>
콩나물 추출물의 유리 아미노산 함량 분석은 자동아미노산분석기(HITACH L-8900)를 이용하여 분석하였다. 표준용액의 제조는 Wako 표준 아미노산 Amino acid Mixture Standard Siolution Type ANⅡ, Type B로부터 각각 2ml를 취하여 0.02N HCl로 희석하여 사용하였다. The free amino acid content of the bean sprouts extract was analyzed using an automatic amino acid analyzer (HITACH L-8900). Standard solutions were prepared by diluting with 0.02 N HCl in 2 ml each from Wako standard amino acid Amino acid Mixture Standard Type II ANII and Type B, respectively.
시험용액의 제조는 시료와 16%트리클로로초산용액을 동량을 넣은 후 15분간 진탕 후 3000rpm에서 15분간 원심분리하여 얻은 상등액을 사용해 분석에 사용하였다. 분석 컬럼은 Column for physiological Fluids Analysis #2622 4.6 × 60 mm 사용하였다.For the preparation of the test solution, the same amount of sample and 16% trichloroacetic acid solution was added thereto, followed by shaking for 15 minutes, centrifugation at 3000 rpm for 15 minutes, and using the supernatant. The analytical column was used with a column for physiological Fluids Analysis # 2622 4.6 × 60 mm.
아미노산 분석 결과(단위 : mg/100 mL)를 하기 표 1에 나타내었다. The results of amino acid analysis (unit: mg / 100 mL) are shown in Table 1 below.
열수추출물General number
Hot water extract
열수추출물Oxygen water (10 ppm)
Hot water extract
열수추출물Oxygen water (20 ppm)
Hot water extract
상기 표 1의 결과를 참조하면 아미노산의 총 함량에서 산소수 열수추출물이 일반수 열수추출물에 비해 더 높게 나타났다. 특히, 우수한 숙취해소효과를 갖는 것으로 알려진 아스파라긴의 함량에서도 산소수 열수추출물은 일반수 열수추출물에 비해 함량이 약 45 내지 70%정도 향상된 것으로 나타났다. Referring to the results of Table 1 above, the total amount of amino acids was higher in the extract of oxygenated water than in the extract of normal water. In particular, the content of asparagine, which is known to have a good hangover effect, was improved by about 45 to 70% as compared with that of a general hydrothermal extract.
상술한 실험결과들을 통해 통상적인 재배수로 재배한 콩나물보다 용존산소농도를 10 내지 20ppm으로 높인 재배수로 재배한 콩나물의 간 손상 억제효과 및 숙취해소효과가 더 우수한 것으로 나타났다. 따라서 숙취해소음료의 재료로서 통상적인 재배수로 재배한 콩나물도 사용할 수 있겠지만 기능성 측면에서 용존산소농도를 높인 재배수로 재배한 콩나물을 사용하는 것이 바람직할 것으로 판단된다. The results of the above tests showed that soybean sprouts cultivated with 10 to 20 ppm dissolved oxygen increased the concentration of dissolved oxygen in soybean sprouts compared to soybean sprouts cultivated in conventional cultivation. Therefore, bean sprouts cultivated by conventional cultivation can be used as a hangover drink, but it is preferable to use bean sprouts cultivated with cultivated water having increased dissolved oxygen concentration in terms of functionality.
<숙취해소음료의 제조>≪ Preparation of hangover drink >
용존산소농도를 15ppm으로 조절한 재배수로 재배한 콩나물을 준비하였다. 준비한 콩나물 100부피부에 대하여 올리고당 20부피부를 혼합한 후 20℃에서 2일간 재운 후 콩나물만을 제거하여 콩나물 추출물을 수득하였다. Soybean sprouts were cultivated with the concentration of dissolved oxygen of 15ppm. 100 parts of the prepared soybean sprouts, 20 parts of oligosaccharide to the skin, mixed with the skin, allowed to stand for 2 days at 20 ° C, and then only the bean sprouts were removed to obtain a soybean sprout extract.
그리고 콩나물 추출물 100중량부에 대하여 헛개나무 열매 5중량부와, 솔잎 5중량부를 혼합하여 혼합물을 준비하였다. 다음으로, 혼합물에 대하여 물을 중량비로 10배를 가한 후 110℃에서 6시간 동안 열수추출한 후 여과하여 복합추출물을 수득하였다. To 100 parts by weight of the bean sprouts extract, 5 parts by weight of Hovenous Fruit and 5 parts by weight of pine needles were mixed to prepare a mixture. Next, water was added to the mixture at a weight ratio of 10 times, followed by hot extraction at 110 ° C for 6 hours, followed by filtration to obtain a combined extract.
그리고 복합추출물 70중량%, 정제수 30중량%를 혼합하여 숙취해소음료를 제조하였다. 70% by weight of the combined extract and 30% by weight of purified water were mixed to prepare a hangover-free beverage.
<숙취해소실험><Hangover elimination experiment>
1. 시험물질1. Test substance
시험물질로 상기 숙취해소음료를 사용하였다. 그리고 양성대조물질로는 시판 중인 숙취음료(여명808, (주)그래미)를 사용하였다. The hangover-free beverage was used as the test substance. As a positive control material, a commercially available hangover beverage (Jeongmi 808, Grammy) was used.
2. 실험동물 및 식이2. Experimental animals and diets
특정병원체 (specific pathogen free)가 없는 5주령, 수컷 SD rat을 (주)오리엔트 바이오(성남, 한국)에서 구입하여 사용하였다. 1주일간의 검역 및 적응과정을 거친 뒤 체중 감소 없는 건강한 동물을 선별하여 실험에 사용하였다, 실험동물은 온도 23±3℃, 상대습도 50±10%, 환기 횟수 10~15 회/시간, 조명시간 12시간(08:00~20:00), 조도 150~300Lux로 설정된 사육환경에서 사육하였다. 1주간의 적응기간 동안 실험동물은 실험동물용 고형사료 ((주) 카길애그리퓨리나, 군산, 한국)와 음수를 자유 섭취하도록 하였다.Five-week-old male SD rats without specific pathogen free were purchased from Orient Bio (Sungnam, Korea). Experimental animals were maintained at a temperature of 23 ± 3 ℃, a relative humidity of 50 ± 10%, a ventilation frequency of 10 to 15 times / hour, and a lighting time 12 hours (08: 00 ~ 20: 00) and the illumination was set at 150 ~ 300 Lux. During the 1-week adaptation period, the experimental animals were fed free of drinking water with the solid feed for experimental animals (Cargill Agri Purina, Gunsan, Korea).
1주간의 적응기간을 거친 후 건강한 동물을 선별하여 난괴법에 의거하여 5개의 군으로 분류하였다. 알코올 + 식염수 260㎎/㎏ body weight/day 경구투여군(무처리군), 알코올 + 숙취해소음료 26㎎/㎏ body weight/day 경구투여군(제1시험군), 알코올 + 숙취해소음료 260㎎/㎏ body weight/day 경구투여군(제2시험군), 알코올 + 숙취해소음료 2000㎎/㎏ body weight/day 경구투여군(제3시험군), 알코올 + 양성 대조물질 41 ㎎/㎏ body weight/day 경구투여군(대조군)으로 분류하고 18 시간 절식시켰다. 실험 당일 체중을 측정하였다. After 1 week of adaptation period, healthy animals were selected and classified into 5 groups based on the nodule method. Alcohol + hangover drink 260 mg / kg Body weight / day Oral administration group (untreated group), alcohol + hangover drink 26 mg / kg body weight / day Oral administration group (first test group) body weight / day oral administration group (second test group), alcohol + hangover elimination drink 2000 mg / kg body weight / day oral administration group (third test group), alcohol + positive control substance 41 mg / kg body weight / (Control group) and fasted for 18 hours. Body weight was measured on the day of the experiment.
숙취해소음료, 양성대조물질, 식염수를 각각 경구투여한 후 30분이 지나서 알코올을 경구투여하였다. 알코올은 발효 주정을 40%로 희석하여 3g/㎏ body weight 투여하였다. 알코올 투여 후 1시간째, 3시간째에 안와정맥에서 채혈하였고, 알코올 투여 후 5시간째에는 심장에서 채혈하였다. 혈액은 serum separate tube(Becton Dickinson, USA)에 담아 30분간 실온에서 방치하고 3,000 rpm에서 20 분간 원심 분리하여 혈청을 분리하였다. 본 실험에서 모든 동물 실험은 한림대학교 동물실험윤리위원회의 승인 하에 수행되었다(Hallym 2013-17).Alcohol was orally administered 30 minutes after oral administration of hangover drink, positive control substance, and saline, respectively. Alcohol was diluted to 40% with 3 g / kg body weight of fermented alcohol. Blood was collected from the orbital vein at 1 hour and 3 hours after alcohol administration and blood was collected from the heart at 5 hours after the administration of alcohol. Blood was collected in a separate serum tube (Becton Dickinson, USA), left at room temperature for 30 minutes, and centrifuged at 3,000 rpm for 20 minutes to separate the serum. All animal experiments were conducted under the approval of Hallym University Animal Experimental Ethics Committee (Hallym 2013-17).
3. 혈청 에탄올 농도 측정3. Measurement of serum ethanol concentration
혈청 내의 에탄올 함량은 에탄올 측정 kit(Abcam)을 사용하여 제조회사에서 제시한 방법에 따라 측정하였다. 혈청을 Assay buffer틀 사용하여 적절하게 희석하여 50㎕를 취한 후 reaction mix preparation을 50㎕첨가하여 1시간 incubation 후 570㎚에서 흡광도를 측정하였다, 에탄올 표준 용액을 사용하여 작성한 표준곡선을 사용하여 혈액 내 에탄올 함량을 산출하였다.The ethanol content in the serum was measured using the ethanol measuring kit (Abcam) according to the manufacturer's method. The serum was diluted appropriately using an Assay buffer frame, and 50 μl of the reaction mix preparation was added, and 50 μl of the reaction mix preparation was added. After incubation for 1 hour, the absorbance was measured at 570 nm. Using the standard curve prepared using the ethanol standard solution, The ethanol content was calculated.
4. 혈청 아세트알데히드 농도 축정4. Determination of serum acetaldehyde concentration
아세트알데히드는 acetaldehyde dehydrogenase 라는 간 효소에 의해 산화되어 acetate를 생성한다. 이 과정에서 NAD+라는 조효소의 도움을 받아 NADH를 생성하는데 그 생성물의 양을 흡광도 340㎚에서 측정한다. 아세트알데히드 측정 kit (R-Biopharm)을 사용하여 제조회사에서 제시한 방법에 따라 측정하였다. Reaction mixture(potassium diphosphate buffer, pH 9.0 + NAD+) 3㎖에 혈청 0.2㎖을 혼합하고 3분간 20℃에서 incubation시킨 다음 340㎚에서 흡광도를 측정(A1)하였다, 여기에 alcohol dehydrogenase를 0.05㎖ 첨가한 다음 5분간 20℃에서 incubation한 후 340㎚에서 흡광도를 측정(A2)하였다, 그 후 아래의 식으로 혈청 내 에탄올 함량을 측정하였다.Acetaldehyde is oxidized by a liver enzyme called acetaldehyde dehydrogenase to produce acetate. In this process, NADH is produced with the aid of a coenzyme called NAD +. The amount of the product is measured at 340 nm in absorbance. The acetaldehyde measurement kit (R-Biopharm) was used according to the manufacturer's method. Reaction mixture (potassium diphosphate buffer, pH 9.0 + NAD +) was mixed with 0.2 ml of serum, incubated at 20 ° C for 3 minutes, and absorbance was measured at 340 nm (Al). After adding 0.05 ml of alcohol dehydrogenase After incubation at 20 ° C for 5 minutes, the absorbance was measured at 340 nm (A2). Then, the ethanol content in the serum was measured by the following equation.
C (g acetaldehyde / L sample solution) = (0.7258 / 6,3) x ΔAC (g acetaldehyde / L sample solution) = (0.7258 / 6,3) x A
ΔA = Sample (A2-A1) - Blank (A2-A1)ΔA = Sample (A2-A1) - Blank (A2-A1)
5. 혈청 ALT, AST, ALP 함량5. Serum ALT, AST, ALP content
부검 당일 채취된 혈액에서 분리한 혈청을 혈액생화학분석기(KoneLab 20 XT, Thermo Fisher Scientific, Waltham, Finland)를 이용하여 alanine aminotransferase(ALT), aspartate aminotransferase(AST), alkaline phosphatase (ALP)를 측정하였다.Serum samples isolated from the blood samples collected on the day of the autopsy were analyzed for alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) using a blood biochemical analyzer (
6. 통계처리6. Statistical processing
모든 분석 수치는 mean ± SEM으로 나타내었다. 수집된 결과는 SAS 9.1 프로그램(SAS Institute, Cary, NC, USA)을 이용하여 통계 분석하였으며, 각 군들의 평균치간의 유의성은 α = 0.05 수준에서 analysis of various와 Duncan's multiple range test에 의해 분석하였다.All analytical values were expressed as mean ± SEM. Statistical analysis was performed using the SAS 9.1 program (SAS Institute, Cary, NC, USA). The significance of each group was analyzed by analysis of various and Duncan's multiple range test at α = 0.05 level.
7. 실험결과7. Experimental results
(1)실험동물의 체중 및 간 무게(1) Weight and liver weight of experimental animals
실험동물의 체중 및 간 무게 측정결과를 하기 표 2에 나타내었다.The results of body weight and liver weighing of the experimental animals are shown in Table 2 below.
무처리군의 평균체중은 211.7±2.6g, 제 1시험군의 평균체중은 212.3±2.8g, 제 2시험군의 평균체중은 212.9±2.7g, 제 3시험군의 평균체중은 211.0±2.3g, 대조군은 212.2±2.9g인 것으로 나타났다. The mean body weight of the untreated group was 211.7 ± 2.6 g, the mean weight of the first test group was 212.3 ± 2.8 g, the mean weight of the second test group was 212.9 ± 2.7 g, and the mean weight of the third test group was 211.0 ± 2.3 g , And the control group was 212.2 ± 2.9g.
(2)혈중 에탄을 농도에 미치는 영향(2) Influence of concentration of ethane in blood
알코올을 투여한지 1시간, 3시간, 5시간 후의 에탄올 농도(g/L)를 하기 표 3에 나타내었다.The ethanol concentration (g / L) after 1 hour, 3 hours and 5 hours after administration of the alcohol is shown in Table 3 below.
상기 표 3을 참조하면, 알코올만을 투여한 무처리군의 경우 1 시간 후 혈청 내 에탄올 농도가 1.520 ± 0.045 g/L 까지 올라갔으며, 시간이 3시간, 5 시간이 경과함에 따라 혈청 내 에탄올 농도는 0.703 ± 0,025 g/L, 0.303 ± 0.006 g/L으로 감소하였다. 알코올을 투여하고 1시간 경과 시 시험군과 대조군의 혈청 내 에탄올 농도가 무처리군에 비해 유의적으로 감소하였으나 시험군의 시험물질 처리 용량에 따른 차이는 나타나지 않았다. 알코올을 투여하고 3시간 경과 시 시험군의 혈청 내 에탄올 농도는 시험물질 처리에 의해 감소하는 경향을 나타냈으나 유의적인 차이를 보이지는 않았다. 알코올을 투여하고 5 시간이 경과하였을 때는 시험군은 혈청 내 에탄올 농도가 유의적으로 감소하였으며 시험물질을 고농도(2,000 ㎎/㎏ body weight)로 투여 시 무처리군에 비해 혈청 내 에탄올 농도가 6,3% 감소하였다. As shown in Table 3, the ethanol concentration in the serum increased to 1.520 ± 0.045 g / L after 1 hour in the alcohol-only treatment group, and the ethanol concentration in the serum increased with the passage of 3 hours and 5 hours 0.703 ± 0.025 g / L and 0.303 ± 0.006 g / L, respectively. The ethanol concentration in the serum of the test group and the control group was significantly lower than that of the untreated group at 1 hour after the administration of alcohol, but no difference was found according to the test substance treatment capacity of the test group. The ethanol concentration in the serum of the test group after 3 hours of alcohol administration was decreased by the test substance treatment but there was no significant difference. The ethanol concentration in the test group was significantly decreased after 5 hours of alcohol administration. When the test substance was administered at a high concentration (2,000 mg / kg body weight), the ethanol concentration in the serum was 6, 3%.
(3)혈중 아세트알데히드 농도에 미치는 영향(3) Influence on blood acetaldehyde concentration
알코올을 투여한지 1시간, 3시간, 5시간 후의 아세트알데히드의 농도(mg/L)를 하기 표 4에 나타내었다.The concentration (mg / L) of acetaldehyde after 1 hour, 3 hours and 5 hours after administration of the alcohol is shown in Table 4 below.
상기 표 4의 결과를 참조하면, 알코올을 투여하고 1시간이 경과하였을 때 무처리군에 비해 시험군과 대조군의 혈청 내 아세트알데히드 농도는 유의적으로 감소하였다. 알코올을 투여하고 3시간 경과 시 시험군은 시험물질 중농도(260 ㎎/㎏ body weight)와 고농도(2,000 ㎎/㎏ body weight)로 투여한 군의 혈청 내 아세트알데히드 농도가 감소하였다. 알코올 투여하고 5시간 경과 시 시험군은 시험물질 처리 농도가 증가함에 따라 혈청 내 아세트알데히드 농도가 유의적으로 감소하였고, 고농도(2,000 ㎎/㎏ body weight)로 시험물질을 처리 시 대조군에 비해 효과적으로 혈청 내 아세트알데히드 농도가 감소하였다. Referring to the results of Table 4 above, the acetaldehyde concentration in the serum of the test group and the control group was significantly lower than that of the untreated group after 1 hour of administration of the alcohol. After 3 hours of alcohol administration, the concentration of acetaldehyde in the serum of the test group (260 ㎎ / ㎏ body weight) and high concentration (2,000 ㎎ / ㎏ body weight) was decreased in the test group. After 5 hours of alcohol administration, acetaldehyde concentration in the serum was significantly decreased as the concentration of the test substance was increased. When the test substance was treated at a high concentration (2,000 mg / kg body weight), serum The acetaldehyde concentration was decreased.
(4)혈청 ALT, AST, ALP에 미치는 영향(4) Effect on serum ALT, AST and ALP
혈청의 ALT, AST, ALP는 하기 표 5에 나타내었다. ALT, AST and ALP of serum are shown in Table 5 below.
상기 표 5의 결과를 참조하면, 혈청 ALT와 AST는 시험군은 시험물질을 고농도 (2,000 ㎎/㎏ body weight)로 처리한 경우 무처리군에 비해 유의적으로 감소하였다. 반면 대조군의 혈청 ALT와 AST는 무처리군에 비해 유의적으로 증가하였다. 혈청 ALT와 AST와 마찬가지로 혈청 ALP도 무처리군에 비해 시험군은 시험물질을 고농도로 처리한 경우 유의적으로 감소하였다. Referring to the results in Table 5, serum ALT and AST were significantly decreased in the test group when the test substance was treated at a high concentration (2,000 mg / kg body weight) as compared with the untreated group. Serum ALT and AST of the control group were significantly increased compared to the untreated group. Similar to serum ALT and AST, serum ALP was significantly lower in the test group than in the untreated group when the test substance was treated at high concentration.
상술한 실험결과를 통해 본 발명의 숙취해소음료는 시판 중인 숙취해소음료와 비교하여 그 효과가 동등하거나 그 이상인 것으로 확인되었다. From the above-described experimental results, it was confirmed that the hangover-eliminating beverage of the present invention had the same or better effects than the commercially available hangover-free beverage.
이상, 본 발명은 일 실시 예를 참고로 설명되었으나 이는 예시적인 것에 불과하며, 당해 기술분야에서 통상의 지식을 가진 자라면 이로부터 다양한 변형 및 균등한 실시 예가 가능하다는 점을 이해할 것이다. 따라서 본 발명의 진정한 보호 범위는 첨부된 청구범위에 의해서만 정해져야 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be clearly understood that the same is by way of illustration and example only and is not to be taken by way of limitation. Accordingly, the true scope of protection of the present invention should be determined only by the appended claims.
Claims (7)
상기 콩나물 100부피부에 대하여 올리고당 20부피부를 혼합한 후 20℃에서 2일간 재운 후 콩나물을 제거하여 콩나물 추출물을 추출하는 제 1추출단계와;
상기 콩나물 추출물 100중량부에 대하여 헛개나무 열매 5중량부와와 솔잎 5중량부를 혼합하여 혼합물을 수득하는 혼합단계와;
상기 혼합물에 대하여 물을 중량비로 10배를 가한 후 110℃에서 6시간 동안 열수추출한 다음 여과하여 복합추출물을 추출하는 제 2추출단계와;
상기 복합추출물에 정제수를 가하여 희석시켜 상기 복합추출물 70중량%, 상기 정제수 30중량%로 조성하는 제형단계;를 포함하며,
상기 재배단계는 25℃의 암실에서 용존산소 농도를 15ppm으로 조절한 상기 재배수를 4시간 간격으로 10분씩 살수하여 6일간 재배하는 것을 특징으로 하는 산화적 스트레스에 의한 간 손상 억제효과를 갖는 콩나물을 이용한 숙취해소음료의 제조방법.Cultivating the bean sprouts by supplying the cultivation water after germinating the soybeans;
A first extraction step of mixing the skin of 100 parts of soybean sprouts with 20 parts of oligosaccharide, and then extracting the soybean sprouts extract by removing the soybean sprouts after lengthening at 20 ° C for 2 days;
Mixing 5 parts by weight of Hovenous Fruit and 5 parts by weight of pine needles with respect to 100 parts by weight of the bean sprouts extract to obtain a mixture;
A second extraction step of adding water to the mixture at a weight ratio of 10 times, followed by hot extraction at 110 ° C for 6 hours, followed by filtration to extract the combined extract;
Adding the purified water to the combined extract to dilute the combined extract to form 70% by weight of the combined extract and 30% by weight of the purified water,
Wherein the cultivation step is carried out by cultivating the cultivated water at a concentration of 15 ppm in a dark room at 25 캜 for 10 minutes at intervals of 4 hours and cultivating the cultivation for 6 days. A method for producing a hangover-resolved beverage.
[Claim 7] The method according to claim 6, wherein the growing step comprises the steps of: a) placing the germinated soybeans in a cultivation vessel and cultivating the cultivated water in a dark room at 20 to 30 DEG C for 5 to 15 minutes at intervals of 2 to 6 hours for primary cultivation for 5 to 7 days; And b) cultivating the bean sprouts which have been firstly cultivated with red light for secondary cultivation for 2 to 4 days. The method according to claim 1, wherein the bean sprouts are bean sprouts. Way.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140009227A KR101548340B1 (en) | 2014-01-24 | 2014-01-24 | Hangover recovery drink using bean sprouts and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140009227A KR101548340B1 (en) | 2014-01-24 | 2014-01-24 | Hangover recovery drink using bean sprouts and manufacturing method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150088671A KR20150088671A (en) | 2015-08-03 |
KR101548340B1 true KR101548340B1 (en) | 2015-08-28 |
Family
ID=53873029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140009227A KR101548340B1 (en) | 2014-01-24 | 2014-01-24 | Hangover recovery drink using bean sprouts and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101548340B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230016437A (en) | 2021-07-26 | 2023-02-02 | 김인자 | Manufacturing method of Wagashi using Blueberry |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101961657B1 (en) * | 2016-10-18 | 2019-03-26 | 대한민국 | Composition comprising bee venom for relieving hangover |
KR102010858B1 (en) * | 2017-09-26 | 2019-08-16 | 대한민국 | Composition for preventing or treating hangover comprising extract from germinated gemmule of bean |
KR20200032460A (en) | 2018-09-18 | 2020-03-26 | 보비씨엔이(주) | Composition containing h2-occluded calcium and having alcoholysis and acetaldehydelysis for hangover-relieving |
KR102186558B1 (en) | 2019-04-30 | 2020-12-03 | 서덕표 | Fungtional beverage for reducing hangover using soybean sprout |
-
2014
- 2014-01-24 KR KR1020140009227A patent/KR101548340B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
http://blog.naver.com/adi777/40195675918* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230016437A (en) | 2021-07-26 | 2023-02-02 | 김인자 | Manufacturing method of Wagashi using Blueberry |
Also Published As
Publication number | Publication date |
---|---|
KR20150088671A (en) | 2015-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100965722B1 (en) | Mushroom culture, preparation methods of the same, and the functional foods comprising the same | |
KR101548340B1 (en) | Hangover recovery drink using bean sprouts and manufacturing method thereof | |
KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
CN102524872B (en) | Ginseng peptide amino acid drink | |
KR102062716B1 (en) | Ripening noni liquid containing do avail the hangover won beverage composition and its manufacturing method | |
KR101406138B1 (en) | Composition for treating and preventing diabetes containing Dendropanoxide from Leaves of Dendropanax morbifera Leveille | |
US20110052732A1 (en) | Mineral absorption accelerator and iron deficiency anemia improver of food composition | |
KR20130041565A (en) | The beverage comprising sap for curing hangover and manufacturing method thereof | |
KR100976241B1 (en) | Extract of sedum sarmentosum for alcohol oxidation and relieves hangover | |
EP2322193B1 (en) | Xanthine oxidase inhibitor and uric acid production inhibitor | |
KR20120044807A (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
KR101408101B1 (en) | Food for improving liver function comprising black rice culture of Lentinus edodes mycelia adding Hovenia dulcis extract as effective component | |
KR20150028664A (en) | Food composition for relieving hangover | |
KR100842839B1 (en) | Anti-hypertensive Beverage Composition Comprising Acanthopanax senticosus and Process for Preparing the Same | |
KR20200045116A (en) | Composition comprising natural complex extract for protecting liver and relieving hangover | |
KR102433586B1 (en) | Food composition for relieving hangover and improving hepatic function | |
KR101034986B1 (en) | Composition comprising the mixed herbal extract for relieving hangover | |
KR101935861B1 (en) | Functional food composition for removing hangover and improving liver function and manufacturing method for thereof | |
KR101999383B1 (en) | Pharmaceutical Composition for Improving, Protecting or Treating Alcoholic Liver Disease comprising Capsosiphon fulvescens Extract as Active Ingredient | |
KR20050029898A (en) | Functional food containing persimmon vinegar powder | |
KR101082598B1 (en) | Hangover recovery drink comprising extracts of Hericium Erinaceum | |
JP4852218B2 (en) | Alcohol metabolism promoter composition | |
JP2007045750A (en) | Anti-fatigue agent | |
KR102614780B1 (en) | Composition for improving hangover and hepatic function comprising ginseng berry extract, dried yeast, and milk thistle extract | |
KR102668792B1 (en) | Health functional food and pharmaceutical composition to help improve sleep quality |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20180613 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190620 Year of fee payment: 5 |